SCHEMBL2854803

SCHEMBL2854803

O=Cc1ccccc1-n1ccnn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 13/20 0.42
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
THRB P10828 1/20 0.41
BLM P54132 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
KEAP1 Q14145 1/20 0.38
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CHRNB2 P17787 1/20 0.36
CYP2B6 P20813 1/20 0.36
MAOA P21397 1/20 0.36
CYP2C19 P33261 1/20 0.36
CHRNA4 P43681 1/20 0.36
HTR3A P46098 1/20 0.36
TRIM24 O15164 2/20 0.35
TRIM33 Q9UPN9 2/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7098104 0.85 NOTUM (0.44) NOTUMKEAP1CYP1A2CYP2C9CHRNB2
SCHEMBL18367778 0.83 NOTUM (0.41) NOTUMMEN1LMNATHRBBLM
SCHEMBL3863178 0.78 NR1H2 (0.42) NOTUMMAOA
SCHEMBL8090136 0.78 NR1H2 (0.42) NOTUMMAOA
SCHEMBL616911 0.77 NOTUM (0.51) NOTUMTDP1CYP1A2CYP2C9CHRNB2
SCHEMBL13106398 0.77 NOTUM (0.49) NOTUMLMNACYP1A2CYP2C9CHRNB2
SCHEMBL613201 0.76 ALDH1A1 (0.51) NOTUMMEN1LMNATHRBBLM
SCHEMBL8109481 0.75 ALDH1A1 (0.53) NOTUMMEN1LMNATHRBBLM
SCHEMBL28858824 0.75 NOTUM (0.49) NOTUMMEN1KMT2ATDP1KEAP1
SCHEMBL27883271 0.73 ALDH1A1 (0.43) NOTUMMEN1LMNATHRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210380548-A1 Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family CTXT PTY LIMITED (AU) 2021-12-09 US disclosed
EP-3676266-A1 FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY Ctxt Pty Ltd (AU) 2020-07-08 EP disclosed
CN-106165684-B Pesticidal compositions and methods relating thereto 陶氏益农公司 2019-06-14 CN disclosed
WO-2019043139-A1 FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY CTXT PTY LIMITED (AU) 2019-03-07 WO disclosed
WO-2019043139-A1 FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY CTXT PTY LIMITED (AU) 2019-03-07 WO disclosed
CN-105025715-B Pesticidal compositions and methods related thereto 美国陶氏益农公司 2018-11-16 CN disclosed
CN-104981160-B Pesticidal compositions and methods related thereto 美国陶氏益农公司 2018-04-20 CN disclosed
CN-104981154-B Pesticidal compositions and methods related thereto 美国陶氏益农公司 2018-01-26 CN disclosed
CN-106413402-A Hepatitis b core protein allosteric modulators 美国印第安纳大学研究和技术公司 2017-02-15 CN disclosed
CN-106165684-A Pesticidal compositions and methods relating thereto 陶氏益农公司 2016-11-30 CN disclosed
CN-104981155-A Pesticidal compositions and methods related thereto DOW AGROSCIENCES LLC 2015-10-14 CN disclosed
US-8263586-B2 OXO bridged diazepan orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2012-09-11 US disclosed
US-20100227848-A1 OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LLC 2010-09-09 US disclosed
EP-1202961-B1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES NOVARTIS AG (CH) 2010-01-20 EP disclosed
EP-2085379-A1 Arylsulfonamido-substituted hydroxamic acid derivatives Novartis AG (CH) 2009-08-05 EP disclosed
CN-101500596-A Macrocyclic oximino hepatitis C protease inhibitors ENANTA PHARM INC (US) 2009-08-05 CN disclosed
US-7138432-B1 Arylsulfonamido-substituted hydroxamic acid derivatives NOVARTIS AG (CH) 2006-11-21 US disclosed
EP-1202961-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES Novartis AG (CH) 2002-05-08 EP disclosed
WO-2001010827-A1 ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES NOVARTIS AG (CH) 2001-02-15 WO disclosed
EP-0010607-B1 TRIAZOLYLSTYRYL COMPOUNDS AND THEIR USE AS WHITENERS FOR ORGANIC MATERIALS BAYER AG (DE) 1981-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380548-A1 Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family KAT5, KAT6A, KAT2A NOTUM 3650/4885MEN1 1280/4885LMNA 4612/4885
US-20100227848-A1 OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR NOTUM 3741/4885MEN1 1976/4885LMNA 3907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.